MIL •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 09/11/2026
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeMIL
Market Capitalization579.28 mln
Float177 mln
Earnings Date11/05/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-2.82
Likely reliable
Relative Strength
13
/ 100
Significantly lagging
Debt / Equity
0.72
Moderate leverage
Pre-Tax Margin
-26%
Deeply loss-making
ROE
-25.76
Deeply negative
Business Description
Evotec SE is a Hamburg-based drug discovery and development company founded in 1993, operating across the United States, Europe, and beyond. The company works to create new treatments for a wide range of serious conditions, including cancer, diabetes, heart disease, kidney and liver disorders, and rare diseases, among others. Evotec partners with leading universities, research hospitals, and major pharmaceutical companies such as Bristol Myers Squibb and Novo Nordisk to advance its work, while also collaborating with biotechnology firms, patient groups, and venture capital investors.
